This is BrainsWay’s global website. The global website is not intended for persons in the United States and includes information on clinical indications that were not cleared by the FDA, which are subject to further US regulatory review for safety and efficacy. BrainsWay D is cleared by the FDA only for patients with MDD who failed to respond to one or more anti-depressants in the current episode, and for patients with OCD as an adjunct treatment.
Brainsway is proud to announce that we have sold our first Deep TMS system within Switzerland. The system was purchased by a clinic focusing on depression and chronic pain management. The CE has certified Deep TMS as a treatment for these indications. The sale of this system is another milestone for the comapny, and a positive indication for their penetration of the European market.
Read more here.